The antifungal pipeline for invasive fungal diseases: what does the future hold?

Expert Rev Anti Infect Ther. 2023 Jun;21(6):577-594. doi: 10.1080/14787210.2023.2203383. Epub 2023 Apr 20.


Introduction: Over the last two decades, we have experienced pressing needs for new additions to the antifungal armamentarium given the emergence of resistant fungi, the growth of at-risk patient populations for invasive fungal diseases (IFD), the high morbidity and mortality associated with IFD.

Areas covered: The current review will discuss the five promising antifungal agents for IFD (i.e. fosmanogepix, ibrexafungerp, olorofim, rezafungin, and opelconazole), now in the late-phase clinical studies, and likely to be available for clinical use in the near future. For each agent, we describe its mechanism of action, pharmacokinetic and pharmacodynamic properties, spectrum of activity as well as the safety and efficacy data, including findings from ongoing clinical trials. The potential roles of these novel antifungals in clinical practice and the key considerations for clinical use will also be discussed.

Expert opinion: There are unmet needs of these novel agents that should be addressed in the future studies. These include defining their indications and benefits, how to best target them appropriately, surveillance and stewardship of their use.

Keywords: Novel antifungals; fosmanogepix; ibrexafungerp; olorofim; opelconazole; rezafungin.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / pharmacology
  • Fungi
  • Humans
  • Invasive Fungal Infections* / drug therapy
  • Mycoses* / drug therapy
  • Risk Factors


  • Antifungal Agents